Diurnal glucose profiles have been compared in ten insulin dependent diabetics receiving, firstly, a twice-daily soluble insulin (SI): isophane insulin (NPHI) regimen containing a high proportion of SI (mean 73%) and, secondly, Mixtard insulin (30% SI, 70% NPHI). For each patient the two regimens gave similar profiles though nocturnal blood glucose control was better on Mixtard. HbA 1 values were similar on the two regimens. The findings show that, using highly purified formulations, small changes in insulin proportions in twice-daily SI : NPHI regimens may be irrelevant to diabetic control; they also suggest that highly purified NPHI may have a substantially shorter duration of action than its older counterpart and that the convenient regimen of twice-daily Mixtard is usually as good as any more complic~ted 'tailormade' regimen of highly purified insulins.
Introduction
Much of the decision making done by physicians caring for patients with insulin dependent diabetes (lDO), and by the patients themselves, relates to the selection and adjustment of insulin doses. Yet few text books pay much attention to this subject beyond listing .the supposed duration of action of commonly used formulations and indicating some of the more widely used insulin combinations. Few attempts have been made either to formalize clinical experience in this field, or critically to examine current practices and teaching.
Several developments are affecting our management of IOD. These include general acceptance of a relationship between blood glucose control and microvascular complications, use of home blood glucose monitoring, introduction of haemoglobin A 1 measurements and the substantial market penetration by highly purified insulins.
The most widely used insulin regimens for management of IDD are probably twice-daily injections of mixed short and intermediate acting insulins (Clarke et al. 1965 , Oakley et al. 1965 .Once such a regime has been established, it is the usual practice for the clinic physician, or patient themselves, to make minor changes in the four daily insulin doses, according to blood or urine tests and the occurrence of insulin reactions. Indeed, apart from checking for, and treating, complications, most clinic physicians would regard adjustment of insulin doses as the major reasons for IDDs attending a diabetic clinic. Physicians and patients should only devote so much time and energy to this aspect of management if it is of proven value. Attention should be given to the following questions, only some of which at present have answers: (I) How accurately is the prescribed dose of insulin given? If day-to-day variations are of the same order as the dose adjustments usually made, then the latter cannot be expected to improve control (Nielsen 1980 , Kesson & Bailie 1980 . A similar argument applies to variable absorption from injection sites (Ginsberg et al. 1973 , Belmonte et al. 1971 .
(2) Are day-to-day variations in diet and exercise so dominant in determining the correct insulin dose that the use of retrospective data in selecting 'to-day's' insulin dose is inappropriate? (3) Do adjustments of the ratio of 'short' to 'intermediate' acting insulin really have the expected effect on modifying the pattern of insulin action, and thus the blood glucose profile? This paper is concerned with the third of these questions, the study being prompted 'by the impression, at least with highly purified soluble insulin (SI) and isophane insulin (NPHI), that the ratio between doses of the two may be less critical than is usually appreciated. Nordisk (Copenhagen) have now marketed SI : NPHI mixtures in both 50 : 50 (lnitard) and 30 : 70 (Mixtard) ratios, and the study now described was formulated in order to discover firstly whether the substitution of a fixed SI : NPH mixture for a 'tailormade' regimen would often lead to worse blood glucose control, and secondly to find out whether the marketing of two combined SI : NPHI formulations is clinically justified.
Methods (Table I) Ten IDDs of widely varying age and disease duration, and recently under the regular diabetic supervision of one of the authors (NWO), were selected for study. They were all receiving twice-daily injections of highly purified SI and NPHI, the former contributing at least 60% of the total daily dose (regimen I).
. . After one or more estimations of HbA 1 as an index of diabetic control, each patient came to hospital for a blood glucose profile. Admission followed normal insulin and breakfast, and samples were taken from an indwelling venous cannula, into fluoride-oxalate, at intervals of 30-120 minutes for the subsequent 22 hours. During this time they were encouraged to be fully mobile, and their usual diet was given according to normal ward routine, the evening meal being at about 19:00 hours. On discharge, patients were changed directly to twice-daily Mixtard insulin, the total morning and evening doses being unchanged (regimen 2). They were instructed to adjust their insulin doses in the usual way, on the basis of blood or urine tests and insulin reactions, and the frequency of clinic attendances and general level of supervision were unaltered.
After a minimum of two months, further HbA l samples were taken and the patients readmitted for a repeat profile during which a dietitian took care that the content and timing of the meals corresponded as closely as possible to that recorded during the first admission. In no case did hypoglycaemic episodes necessitating additional carbohydrate occur during profiles.
The study was devised in order to discover whether a single formulation could provide control as good as that obtained with a 'tailormade' regimen, and therefore the pre-mixed insulin was given after the more complicated regimen on which the patient had already been 'stabilized', rather than using a randomizing protocol.
Glucose was estimated by a standard autoanalyser glucose oxidase method and glycosylated Hb by the method of Welch & Boucher (1978) . As patients acted as their own controls, it was not thought necessary to measure either circulating C-peptide or insulinbinding antibodies.
Results
The mean SI content of regimen 1 was 73% (27% NPH), almost exactly the reverse of regimen 2. The mean HbA 1 values for regimens 1 and 2 were 12.5± 1.6% and 11.9± 1.1%respectively (NS). The mean diurnal blood glucose profiles on the two regimens are shown in Figure 1 . The greater proportion of long-acting insulin in regimen 2 led to significantly better control during the latter part of the night, but otherwise there were no important differences between the mean values at individual times, and the overall mean blood glucose values did not differ significantly from one another. Mean data give an incomplete picture, so the individual profiles are shown in Figure 2 . These indicate that there was more variation between patients than between regimens. Patients MW, BM, PW and RC all had similar profiles with high values during the afternoon, and better control following the evening injection; in RC an improvement in control was seen on regimen 2, but the other three patients showed almost unchanged patterns. In contrast JR, EF, KP and KR showed flatter profiles, and while, in three of them, regimen 2 again gave better nocturnal blood glucose control. the profile shape was similar with the two regimens.
Discussion
The inconvenience of insulin injections is compounded, particularly in diabetics with visual impairment, by doses drawn up from separate bottles and mixed in the syringe; is this additional inconvenience worthwhile? When ten IDDs were changed from highly purified SI : NPHI regimens in which SI predominated, to Mixtard insulin, no patient showed worse control. Indeed, for both regimens the mean blood glucose was lower before lunch than during the afternoon, suggesting that at least in some patients the addition of even as little as 30% SI may be inappropriate; it is common practice in Denmark (Deckert & Lerup 1976) , and in some British centres, to' start treatment of IDDs on twice-daily highly purified NPHI (Insulatard) adding SI only if required.
As all the patients had received older, less pure, insulin formulations in the past, it is likely that insulin-binding antibodies were present in the majority of them, at least at the start of the study. Yet the profiles showed clearly that the main problem with both regimens studied was inadequate duration of insulin action rather than the reverse, a problem that might be even more evident in patients not previously treated with insulin. The reason for patients often receiving high proportions of SI in mixed regimens dates back to the use of twice-daily SI before the introduction of longer-acting insulins; when the latter were added, regimens in which the SI dose substantially exceeded that of NPHI were often found to be the most appropriate. Indeed, the 50 : 50 Initard formulation was introduced because British physicians were sceptical about Mixtard having adequate early insulin action. It seems likely that, perhaps as a result of lower insulin-binding antibody concentrations, the effective duration of action of nominally similar insulins is now considerably shorter than that of their older counterparts, and that this should be taken into account when prescribing. It may, moreover, be a factor in the increased awareness of the twin problems of nocturnal hypoglycaemia and rapidly rising blood glucose levels before breakfast (Oakley et al. 1967 , Gale & Tattersall 1979 .
There is little literature comparable to this study. It is, however, of interest to reanalyse the data of Phillips et al. (1979) who described dosage schedules for treating non-insulin dependent diabetics with Actrapid and Ultratard (UL) insulins. With increasing severity of the disease, as judged by fasting blood glucose, the proportion of short to extended action insulin increased, as shown in Figure 3 . This figure suggests that in patients without endogenous insulin action, about 40% of insulin is required for control of basal blood glucose and 60% for handling acute requirements in response to meals. The present findings therefore suggest that, using highly purified SI and NPHI, the latter must make an appreciable contribution to handling meal carbohydrate as well as controlling the basal blood glucose. Phillips et al. 1979) In view of the difficulties encountered in preventing pre-supper and pre-breakfast hyperglycaemia with Mixtard insulin, one can speculate that the development of nonantigenic SI and NPHI may have actually made it more, rather than less, difficult to use these insulins on a twice-daily basis for controlling IDD.
